London, UK – 28 August 2025 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company’s proprietary lateral CAR platform, today announced that it will attend the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. Filippo Petti, Chief Executive […]